Journal article

Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials

C Seshadri, JAL Flynn, P Maiello, D Schnappinger, RJ Wilkinson, SB Gordon, HC Mwandumba, KC Jambo, DF Hoft, EJ Rubin, E Jamrozik, SM Fortune, JG Kublin

Lancet Microbe | Published : 2026

Open access

Abstract

Controlled human infection models (CHIMs) can accelerate vaccine development for infectious diseases. Mycobacterium tuberculosis is a human-adapted pathogen that is the leading infectious cause of death worldwide. M tuberculosis infection results in a spectrum of clinical outcomes that are incompletely modelled in animals. To date, the risks of infection, prolonged treatment, and sequelae related to CHIMs with M tuberculosis have been considered ethically unacceptable. However, recent advances in bacterial engineering have resulted in safe strains that could permit M tuberculosis CHIM studies with reduced risks. In this Personal View, we address the practical considerations for conducting a ..

View full abstract

University of Melbourne Researchers